SILVER SPRING
Afrezza cleared for pediatric diabetes
- Sponsor
- MannKind Corporation $MNKD
- Drug
- Afrezza · insulin human
- Indication
- diabetes
FDA approved inhaled insulin Afrezza for children and adolescents aged 6+ with diabetes.
What this means
Afrezza is an inhaled insulin powder that works faster than traditional insulin shots by absorbing quickly through the lungs. Today FDA expanded its approval to include children and adolescents aged 6 and older with diabetes. This decision could offer younger patients a needle-free insulin option that may fit better into their daily routines.